MINNEAPOLIS, Dec. 14,
2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that Lunaphore, a Bio-Techne brand, and SIB
Swiss Institute of Bioinformatics, have been awarded Innosuisse
funding for an innovation project. The collaboration aims to
develop novel AI-based assay development tools for spatial biology
on Lunaphore's COMET™ to further accelerate the adoption of
multiplex sequential immunofluorescence (seqIF™) technology in
research.
Spatial biology utilizes detailed tissue analysis and
intracellular interactions to enable profound insights in cancer
biology, immuno-oncology, and other research fields. However,
technical hurdles still stand in the way of spatial biology
technologies entering clinics and becoming guiding tools for
personalized therapies.
Lunaphore's COMET product suite provides the first universal,
end-to-end spatial biology solution, answering the needs of the
scientific community in translational and clinical research. COMET
is the only fully automated, high-throughput, hyperplex platform
ensuring scalability and reproducibility without the need to
conjugate primary antibodies, making panel design much more
flexible and faster than any other hyperplex solution.
COMET's seqIF approach is a valuable tool for advancing spatial
biology adoption in the clinic. The collaboration will focus on
automating standardized multiplex immunofluorescence (mIF)
protocols, with the machine learning-based tools expected to enable
researchers to further reduce mIF's technical complexity and
eliminate human-driven error. AI techniques developed by SIB will
further enhance the platform's automated approach, and aim to
ensure the robustness of protocol transfer to virtually any tissue.
In the long term, the project has the potential to improve human
health and reduce healthcare costs by implementing automated
leading-edge technology and accelerating the discovery of
next-generation therapeutic interventions.
"The COMET platform is revolutionizing spatial biology by making
spatial technologies more accessible to every lab," said
Kim Kelderman, Bio-Techne's Chief
Operating Officer. "With a focus on novel AI-based approaches for
assay development, this scientific collaboration is a unique
project that will empower scientists to reach their research goals
more efficiently and develop the next generation of personalized
therapies."
"This new collaboration with Lunaphore is an excellent
opportunity to showcase SIB's expertise in AI to support innovation
and state-of-the-art technological developments in the medtech
sector," said Aitana Neves, Team
Lead Data Science at the SIB Clinical Bioinformatics Group.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $1.1
billion in net sales in fiscal 2023 and has approximately
3,200 employees worldwide. For more information on Bio-Techne and
its brands, please visit https://www.bio-techne.com or follow the
Company on social media at: Facebook, LinkedIn, Twitter or
YouTube.
About the SIB Swiss Institute of Bioinformatics
SIB is an internationally recognized non-profit organization,
dedicated to biological and biomedical data science. Our data
scientists are passionate about creating knowledge and solving
complex questions in many fields, from biodiversity and evolution
to medicine. They provide essential databases and software
platforms as well as bioinformatics expertise and services to
academic, clinical, and industry groups. SIB federates the
Swiss bioinformatics community of some 900 scientists, encouraging
collaboration and knowledge sharing. The institute contributes
to keeping Switzerland at the
forefront of innovation by fostering progress in biological
research and enhancing health.
For further information on Lunaphore
contact:
Lindsey Rodger, Head
of Communications
Email: communications@lunaphore.com
Bio-Techne Corporation (NASDAQ: TECH)
David Clair, Vice President, Investor Relations
& Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lunaphore-and-sib-awarded-innosuisse-funding-to-develop-innovative-ai-based-assay-development-tools-302015041.html
SOURCE Bio-Techne Corporation